F. Tas Et Al. , "Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer," CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.77, no.1, pp.127-131, 2016
Tas, F. Et Al. 2016. Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer. CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.77, no.1 , 127-131.
Tas, F., Karabulut, S., Serilmez, M., KARABULUT, M., & Duranyildiz, D., (2016). Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer. CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.77, no.1, 127-131.
Tas, Faruk Et Al. "Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer," CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.77, no.1, 127-131, 2016
Tas, Faruk Et Al. "Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer." CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.77, no.1, pp.127-131, 2016
Tas, F. Et Al. (2016) . "Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer." CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.77, no.1, pp.127-131.
@article{article, author={Faruk TAŞ Et Al. }, title={Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer}, journal={CANCER CHEMOTHERAPY AND PHARMACOLOGY}, year=2016, pages={127-131} }